OTSUKA HOLDINGS CO., LTD.
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 34.3K
- Market Cap
- $32.5B
- Website
- http://www.otsuka.com
Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
A Study Investigating the Effects of a Novel Mindfulness Approach on Frequency and Duration of Meditation and Self-Reported Stress and Mood in Generally Healthy Adults
- Conditions
- Health Knowledge, Attitudes, Practice
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Otsuka Holdings Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT05832645
- Locations
- 🇺🇸
Biofortis Innovation Services, Addison, Illinois, United States
News
Vera Therapeutics' Atacicept Achieves 46% Protein Reduction in Phase 3 IgA Nephropathy Trial
Vera Therapeutics' atacicept demonstrated a statistically significant 46% reduction in proteinuria in patients with IgA nephropathy, exceeding the 35% reduction seen in Phase 2 trials.
Taiho Pharmaceutical to Acquire Swiss ADC Pioneer Araris Biotech for Up to $1.14 Billion
Taiho Pharmaceutical will acquire Araris Biotech for $400 million upfront with potential milestone payments of up to $740 million, valuing the deal at $1.14 billion.
Global Polycystic Kidney Disease Clinical Trials Landscape Mapped in Comprehensive 2025 Review
New comprehensive report provides critical insights into the global clinical trial landscape for Polycystic Kidney Disease, covering regional distribution, trial phases, and sponsor involvement across G7 and E7 countries.